Image and reality: drugs for the future Pharmaceutical manufacturers share some of the characteristics of policemen and pawnbrokers; most people see them in blackand-white terms either as villains or as assets to our society. These polarised responses have become apparent recently in the public response to claims by the industry that new drugs cost so much to develop and take so long to test that innovation will soon no longer be cost effective. Certainly fewer new drugs are being marketed than 20 years ago-but might that not be simply because the drug explosion is over ? Major innovations, such as H2-receptor antagonists as treatments for peptic ulcer, can still make vast profits for the companies concerned. Does it really matter if the flow of new diuretics, tranquillisers, and hypotensive drugs is slowing ?
These questions were examined at a conference last month in Oslo organised by the Association of Norwegian Representatives of Foreign Pharmaceutical Manufacturers. Speakers were quick to assert that the current generation of drugs were the results of 15 to 20 years' gestation and that without some change the pace of innovation would continue to slow.
The clear message from the research units was that there was no shortage of new, promising areas for development. The genetic manipulation of bacteria, though still in its early stages, had already produced human growth hormone and human insulin, so solving the problems of short supply that had threatened to become major anxieties for clinicians. Monoclonal antibodies were revolutionising diagnostic techniques in the laboratory. More antiviral drugs and antiviral vaccines were being developed with greater specificity and less toxicity. Whole topics of pharmacological research, such as the prostacyclin-thromboxane system, were just yielding their first products for clinical assessment.
Yet 
